Harnessing Patient-Derived ex vivo Models to Empower Immunotherapy & ADC Combination Development
Time: 11:30 am
day: Day 2 Track B AM
Details:
- Explaining the need and advantages of using tumor explants to remodel the tumor immune microenvironent and better understand tumor biology
- Assessing strategies to implement patient-derived tumor explant models from tissue slices to study drug interactions in a spatial context
- Sharing the future hopes to combine the different model and assays to develop combination strategies for ADC and IO agents and simulate patient response
